Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• JACC Spotlight Issue Provides Expert Insight on 2026 Dyslipidemia Guideline
  A special JACC Spotlight Issue supporting the recently published 2026 ACC/AHA Guideline on the Management of Dyslipidemia, offers commentaries that provide a comprehensive overview of the new guideline recommendations and expert insights into understanding the science behind the recommendations...
• FDA Update: Agency Approves Baxdrostat to Treat Adults With HTN
  The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is not adequately controlled with other antihypertensive medications.
• SURMOUNT-MAINTAIN: Continuing Tirzepatide Maintains Weight Loss
  In patients with obesity, continuing tirzepatide at either the maximum tolerated dose (MTD) of 10 or 15 mg or a reduced dose of 5 mg was safe and effectively maintained weight loss along with its associated health benefits, compared to switching to placebo, according to results from the SURMOUNT-MAINTAIN trial published May 12 in The […]
• ACC CardiaCast: In Case You Missed It: ACC.26 ATTR-CM Treatment Updates
  This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released late-stage clinical trial data for currently available disease-modifying therapies.
• Did Disparities in ICD Implantations Worsen During the COVID-19 Pandemic? | NCDR Study
  The incidence of ICD implantations declined significantly during the COVID-19 pandemic, according to a recent study published in Heart Rhythm. Although disparities by sex, race and ethnicity persisted during peak COVID, they did not worsen.